Candel Therapeutics (CADL) Short term Debt (2020 - 2025)

Candel Therapeutics has disclosed Short term Debt across 4 years of filings, most recently posting $4.2 million for Q3 2025.

• Short term Debt for Q3 2025 came in at $4.2 million, down 57.11% year-over-year; the trailing twelve-month figure through Sep 2025 was $4.2 million (down 57.11% YoY), and the FY2024 annual result was $9.9 million, up 11.27% from the prior year.
• Short term Debt came in at $4.2 million for Q3 2025 at Candel Therapeutics, down from $6.7 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.9 million in Q4 2024 to a low of $1.3 million in Q1 2023.
• The 3-year median for Short term Debt is $8.9 million (2023), against an average of $7.2 million.
• Across the five-year window, Short term Debt surged 679.49% in 2024 and tumbled 57.11% in 2025, its largest moves.
• Candel Therapeutics' Short term Debt stood at $8.9 million in 2023, then rose by 11.27% to $9.9 million in 2024, then plunged by 57.3% to $4.2 million in 2025.
• The last three Short term Debt figures came in at $4.2 million (Q3 2025), $6.7 million (Q2 2025), and $9.2 million (Q1 2025), per Business Quant data.